{
  "emaEpar": [
    {
      "activeSubstance": "pazopanib",
      "conditionIndication": "Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.",
      "inn": "pazopanib",
      "marketingAuthorisationDate": "2010-06-14 00:00:00",
      "marketingAuthorisationHolder": "Novartis Europharm Limited\u00a0",
      "medicineName": "Votrient",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/votrient"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Pazopanib",
  "nciThesaurus": {
    "casRegistry": "444731-52-6",
    "chebiId": "",
    "chemicalFormula": "C21H23N7O2S",
    "definition": "A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.",
    "fdaUniiCode": "7RN5DR86CK",
    "identifier": "C74547",
    "preferredName": "Pazopanib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C155727",
      "C159198",
      "C159199",
      "C93259"
    ],
    "synonyms": [
      "Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-",
      "GW786034",
      "PAZOPANIB",
      "Pazopanib"
    ]
  }
}